

Allergy Immunotherapy Market to Reach \$4.9 Billion by 2033, Growing at 10.4% CAGR

The allergy immunotherapy market is expected to soar from \$1.8 billion in 2023 to an impressive \$4.9 billion by 2033, growing at a robust CAGR of 10.4%

WILMINGTON, DE, UNITED STATES, December 16, 2024 / EINPresswire.com/ -- The <u>allergy</u> <u>immunotherapy market</u> is witnessing unprecedented growth, with its valuation expected to soar from \$1.8 billion in 2023 to an impressive \$4.9



billion by 2033, growing at a robust CAGR of 10.4% over the next decade. This remarkable trajectory is fueled by rising allergy prevalence, increased focus on personalized medicine, and advances in immunotherapy treatments. A new report by Allied Market Research, titled "Allergy Immunotherapy Market by Type, Application, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2024–2033," sheds light on the key drivers, challenges, and opportunities shaping this dynamic industry.

Get Sample PDF Copy: <u>https://www.alliedmarketresearch.com/request-sample/A10241</u>

Key Drivers of Allergy Immunotherapy Market Growth

1. Rising Prevalence of Allergies

The escalating number of allergy cases globally is a major factor driving demand for allergy immunotherapy. Conditions such as allergic rhinitis, asthma, and food allergies are becoming increasingly common, necessitating more effective and long-term treatment solutions. Immunotherapy, which targets the root cause of allergies rather than just alleviating symptoms, is rapidly gaining traction among patients and healthcare providers alike.

2. Focus on Personalized Medicine

The shift toward tailored treatment approaches is revolutionizing allergy care. Personalized immunotherapy plans, designed to address individual sensitivities and conditions, are enhancing patient outcomes and satisfaction. This trend is expected to play a pivotal role in the growth of the allergy immunotherapy market.

3. Technological Advancements in Immunotherapy

Ongoing research and development efforts are leading to significant innovations in allergy immunotherapy. For instance, sublingual immunotherapy (SLIT) tablets and advanced drug delivery systems are making treatments more effective and convenient for patients. These advancements are creating lucrative opportunities for market expansion.

Challenges: The Risk of Side Effects

Despite its promise, allergy immunotherapy is not without challenges. The risk of side effects, such as local reactions or anaphylaxis, remains a concern for both patients and providers. While these risks are generally low and manageable, they underscore the need for rigorous safety protocols and ongoing patient monitoring.

Allergy Immunotherapy Market Segment Highlights

By Type: Subcutaneous Immunotherapy (SCIT) Leads the Way

Subcutaneous immunotherapy (SCIT) is the cornerstone of allergy treatment, holding the highest market share in 2023. Administered through regular injections, SCIT desensitizes the immune system to allergens over time, offering long-lasting relief even after treatment concludes. Its well-established safety profile and efficacy make it a trusted choice for managing severe allergies. On the other hand, sublingual immunotherapy (SLIT) is gaining popularity for its ease of use, allowing patients to administer treatment at home via oral tablets or drops. SLIT is particularly appealing for pediatric and elderly patients, as it eliminates the need for frequent clinic visits.

By Application: Allergic Rhinitis Drives Demand

Allergic rhinitis is the most common condition treated with immunotherapy, contributing significantly to market growth. This chronic condition, characterized by symptoms like nasal congestion, sneezing, and itchy eyes, affects millions worldwide. Unlike symptomatic treatments, immunotherapy offers a long-term solution by addressing the underlying immune response, making it an increasingly preferred option.

Other key applications include asthma, food allergies, and atopic dermatitis, with all segments poised for substantial growth as awareness of immunotherapy's benefits continues to rise.

By Distribution Channel: Hospitals at the Forefront

Hospital pharmacies dominate the distribution landscape for allergy immunotherapy, ensuring patients receive safe and effective treatments under medical supervision. These pharmacies play a critical role in dispensing allergen extracts, managing inventory, and providing expert guidance on administration.

Meanwhile, retail and online pharmacies are gaining ground, driven by the growing preference for home-based treatment options like SLIT. The convenience of online platforms, coupled with competitive pricing, is expected to further boost this segment.

Have Any Query? Ask Our Expert: <u>https://www.alliedmarketresearch.com/purchase-enquiry/A10241</u>

Allergy Immunotherapy Market Regional Outlook

North America and Europe: Market Leaders

North America and Europe currently lead the global allergy immunotherapy market, thanks to: • Advanced healthcare infrastructure.

- High prevalence of allergies.
- Strong focus on innovation and research.

These regions also benefit from supportive regulatory environments and well-established distribution networks, ensuring widespread access to cutting-edge treatments.

Asia-Pacific: A Lucrative Growth Frontier

Asia-Pacific is emerging as a key growth market, driven by rising healthcare investments and increasing awareness of allergic conditions. Countries like China, India, and Japan are witnessing a surge in demand for immunotherapy as disposable incomes rise and healthcare systems improve.

Latin America and the Middle East

These regions are gradually adopting allergy immunotherapy, supported by advancements in healthcare infrastructure and a growing focus on managing chronic diseases. While still in the early stages, these markets hold significant potential for future growth.

Competitive Landscape

The global allergy immunotherapy market is fiercely competitive, with major players continuously innovating to maintain their edge. Key companies include:

- ALK-Abelló A/S
- Stallergenes Greer
- Torii Pharmaceutical Co., Ltd.
- Merck KGaA
- Biomay AG
- Allergy Therapeutics
- HAL Allergy Group
- Leti Pharma
- Allovate, LLC

These players are leveraging strategies such as product launches, clinical trials, partnerships, and regional expansions to capture a larger share of the market.

Recent Allergy Immunotherapy Industry Developments

1. Regulatory Milestone by ALK-Abelló A/S

In May 2024, ALK-Abelló A/S announced a major regulatory filing in Europe for ITULAZAX, a tree pollen SLIT tablet for young children. This development marks a significant step forward in expanding immunotherapy options for pediatric patients.

2. Stallergenes Greer's Tech Partnership

In October 2021, Stallergenes Greer partnered with Aptar Pharma to develop a groundbreaking connected device and companion mobile app for sublingual allergy immunotherapy. This innovation aims to enhance treatment adherence and patient engagement, setting a new

standard for digital healthcare in immunotherapy.

Allergy Immunotherapy Market Future Outlook: What Lies Ahead The allergy immunotherapy market is on the cusp of transformative growth, driven by technological advancements, increasing awareness, and a shift toward long-term, personalized treatments. Key trends expected to shape the market include:

• Digital Health Integration: Wearable devices and mobile apps will play a larger role in monitoring and managing immunotherapy treatments.

• Expansion into Emerging Markets: Developing regions, particularly in Asia-Pacific and Latin America, will witness accelerated adoption of allergy immunotherapy as healthcare infrastructure improves.

• Enhanced Patient-Centric Solutions: Innovations like needle-free delivery systems and allergenspecific treatments will make immunotherapy more accessible and appealing to a broader patient base.

The global allergy immunotherapy market is set to redefine how allergies are treated, offering hope to millions of patients worldwide. As the industry moves toward personalized, technology-driven solutions, it holds immense potential for improving patient outcomes and quality of life. With a projected valuation of \$4.9 billion by 2033, this market is a testament to the growing importance of addressing allergies as a critical healthcare priority. For stakeholders, including healthcare providers, pharmaceutical companies, and investors, the next decade presents a wealth of opportunities to make a lasting impact in this evolving field.

Thanks for reading this article; AMR also offers Custom Research services providing focused, comprehensive and tailored research according to clientele objectives. Thanks for reading this article; you can also get individual chapter wise sections or region wise reports like North America, Europe, or Asia.

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa Allied Market Research +1 800-792-5285 email us here Visit us on social media: Facebook X This press release can be viewed online at: https://www.einpresswire.com/article/769474248

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.